Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPISTOP: Nintedanib for Epistaxis in Hereditary Haemorrhagic Telangiectasia
2024-518886-89-00Phase 2Authorised
- Sponsor
- Hospices Civils de Lyon
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial in hereditary hemorrhagic telangiectasia (HHT) comparing Nintedanib arm with Placebo arm (2 arms). Planned start May 2025; status: authorised.
02
Drugs
nintedanib
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on 2024-518886-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518886-89-00.